Press Releases
| Su | Mo | Tu | We | Th | Fr | Sa |
|---|---|---|---|---|---|---|
| Su | Mo | Tu | We | Th | Fr | Sa |
|---|---|---|---|---|---|---|
-
Sep 20, 2020New Results Include Findings From the Phase 2 LEAP-004 Trial Showing an ORR of 21.4% in Patients With Unresectable or Advanced Melanoma Who Had Previously Progressed on an Anti-PD-1/PD-L1 Therapy
KENILWORTH, N.J., and WOODCLIFF LAKE, N.J., Sept. 20, 2020 – Merck (NYSE: MRK), known as MSD outside the United States and Canada, and Eisai today announced new investigational data from two...
-
Sep 10, 2020Data to include key findings from the LEAP (LEnvatinib And Pembrolizumab) clinical trial program evaluating the combination across multiple cancers including melanoma, non-small cell lung cancer (NSCLC) and six new tumor types
Eisai will present two late breakers and 10 e-posters at the European Society for Medical Oncology (ESMO) Virtual Congress 2020 from September 19-21, 2020. Notable data from ongoing LEAP clinical...
Aug 11, 2020Eisai Inc. announced today the topline results from Study 211, a Phase 2 trial evaluating the efficacy and safety of LENVIMA, an orally available multiple receptor tyrosine kinase inhibitor...
Jul 8, 2020KENILWORTH, N.J., and WOODCLIFF LAKE, N.J., July 8, 2020 – Merck (NYSE: MRK), known as MSD outside the United States and Canada, and Eisai today announced that the U.S. Food and Drug...
- May 29, 2020Results showed encouraging anticancer activity in both first-line and later lines, with an objective response rate (ORR) of 25.8% and 21%, respectively
Eisai today announced updated results from ENHANCE 1, a Phase 1b/2 study exploring the investigational combination of eribulin plus pembrolizumab in patients with metastatic triple-negative breast...
- May 28, 2020Analyses from KEYTRUDA Plus LENVIMA Trials to be Presented at 2020 ASCO Annual Meeting
KENILWORTH, N.J., and WOODCLIFF LAKE, N.J., May 28, 2020 – Merck (NYSE: MRK), known as MSD outside the United States and Canada, and Eisai today announced new data from analyses of two trials...
- May 13, 2020- Data highlighted shows continued progress on clinical trials for the KEYTRUDA plus LENVIMA combination across multiple tumor types, including a virtual oral presentation on the Phase 2 results of the metastatic clear cell renal cell carcinoma (mccRCC) cohort of a Phase 1b/2 study of KEYTRUDA plus LENVIMA
Eisai announced today the presentation of data and analyses across six cancer types at the American Society of Clinical Oncology's ASCO20 Virtual Scientific Program from May 29-31. Data from...
-
Mar 19, 2020
Eisai announced today that positive results from a Phase 2 study (Study 111/KEYNOTE-146) of lenvatinib (marketed as LENVIMA®), an orally available kinase inhibitor discovered by Eisai, in...
- Feb 15, 2020-- Results from a Phase 2 trial presented at ASCO GU 2020
Eisai presented today results from a Phase 2 trial assessing the efficacy and safety of lenvatinib (marketed as LENVIMA®) in combination with everolimus (LEN+EVE) in patients with unresectable...
-
Feb 10, 2020
Eisai announced today the presentation of three abstracts at the 2020 Genitourinary Cancers Symposium (#GU20) in San Francisco from February 13-15. New data to be presented on lenvatinib (marketed...